ライフサイエンスコーパス: nonsmall-cell lung cancer

1 ession and tumorigenesis in human breast and nonsmall cell lung cancer.

2 , including ovarian, breast, pancreatic, and nonsmall cell lung cancer.

3 maintenance therapy of colorectal cancer and nonsmall cell lung cancer.

4 of involvement for patients with metastatic nonsmall cell lung cancer.

5 ts with a variety of solid tumors, including nonsmall cell lung cancer.

6 been shown to be a hot spot (67%) for LOH in nonsmall cell lung cancer.

7 herapy in patients with inoperable stage III nonsmall cell lung cancer.

8 nnate immune response in some tumors such as nonsmall cell lung cancer.

9 ly advanced or metastatic KRAS(G12C)-mutated nonsmall-cell lung cancer.

10 as well as cytokines such as IL-6, in human nonsmall cell lung cancers.

11 Tumor histology included 68 nonsmall cell lung cancer, 34 renal cancer, 18 colorecta

12 s, leading to the emergence of resistance in nonsmall cell lung cancer and other tumor types.

13 edition also improved prognostic staging for nonsmall cell lung cancer and reclassified 26.4% of stag

14 impact on the clinical care of patients with nonsmall-cell lung cancer and squamous cell carcinoma of

15 ceptor (EGFR) inhibitors in the treatment of nonsmall-cell lung cancer and the treatment of squamous

16 uation in patients with stage III inoperable nonsmall cell lung cancer based on RECIST 1.1.

17 Here we demonstrate that multiple nonsmall cell lung cancer cell lines demonstrate constit

18 xhibited potent antiproliferative effects in nonsmall cell lung cancer cell lines harboring SRC activ

19 between breast, esophageal, colorectal, and nonsmall cell lung cancer cell lines, as well as heterog

20 e CACNA2D2 gene transfer in 3p21.3-deficient nonsmall cell lung cancer cell lines.

21 nt cytotoxicity in A375 (melanoma) and H292 (nonsmall cell lung cancer) cell lines, while demonstrati

22 es have been detected with high frequency in nonsmall cell lung cancer cells (NSCLC) and contribute t

23 ions was observed in pancreatic (PANC-1) and nonsmall cell lung cancer cells (NSCLC, NCI-H460) of 80-

24 to previous studies in other cell types, in nonsmall cell lung cancer cells survivin was expressed i

25 ues for USP1/UAF1 inhibition and activity in nonsmall cell lung cancer cells, specifically increased

26 In experiments with NCI-H1299 human nonsmall cell lung cancer cells, the cytotoxicity of the

27 izes filamentous actin in vitro and in A549 (nonsmall cell lung cancer) cells, inhibits growth of can

28 De novo nonsmall cell lung cancer, colon cancer, breast cancer,

29 onstrated to induce a significant portion of nonsmall cell lung cancer-derived angiogenic activity an

30 ients with first, primary, clinical stage IA nonsmall cell lung cancer from a large cohort undergoing

31 Recurrent gene rearrangements in nonsmall cell lung cancer fuse EML4 to anaplastic lympho

32 The management of skeletal metastases from nonsmall cell lung cancer is evolving as biochemical mar

33 ment of skeletal metastases in patients with nonsmall cell lung cancer is evolving as improved treatm

34 The A549 nonsmall cell lung cancer line is widely used as a model

35 datory to perform MLNR when screen-diagnosed nonsmall cell lung cancer manifests as a subsolid nodule

36 profiling for miRNAs in a cohort of stage 1 nonsmall cell lung cancers (n = 81) and determined that

37 e antifolate used for therapy of nonsquamous nonsmall cell lung cancer (NS-NSCLC).

38 at the expression of FUT8 is up-regulated in nonsmall cell lung cancer (NSCLC) and correlates with tu

39 and women, and the majority of patients with nonsmall cell lung cancer (NSCLC) are over 65 years of a

40 function to be approved for the treatment of nonsmall cell lung cancer (NSCLC) by the FDA, demonstrat

41 ssion and its overexpression is critical for nonsmall cell lung cancer (NSCLC) cell growth in vitro a

42 sublines of PC9, a commonly used EGFR mutant nonsmall cell lung cancer (NSCLC) cell line.

43 d 13b was further tested against a series of nonsmall cell lung cancer (NSCLC) cell lines in which it

44 In vitro cytotoxicity toward a number of nonsmall cell lung cancer (NSCLC) cell lines revealed on

45 ll cell lung cancer cell lines (SCLC), 13/14 nonsmall cell lung cancer (NSCLC) cell lines, and 1/2 br

46 of the ubiquitin E3 ligase FBXO22 sensitizes nonsmall cell lung cancer (NSCLC) cells to ionizing radi

47 n to be highly effective in the treatment of nonsmall cell lung cancer (NSCLC) harboring oncogenic EG

48 Treatment of advanced nonsmall cell lung cancer (NSCLC) has rapidly changed ov

49 to standard treatment paradigms for advanced nonsmall cell lung cancer (NSCLC) have been successful,

50 the 5-year recurrence with localized stage I nonsmall cell lung cancer (NSCLC) is 18.4%-24%.

51 Nonsmall cell lung cancer (NSCLC) is one of the leading

52 Because resection of early stage nonsmall cell lung cancer (NSCLC) is primary therapy, we

53 Nonsmall cell lung cancer (NSCLC) is the leading cause o

54 s and matched noncancerous lung tissues from nonsmall cell lung cancer (NSCLC) patients, and we compa

55 r, has the potential to improve outcomes for nonsmall cell lung cancer (NSCLC) patients.

56 Advanced nonsmall cell lung cancer (NSCLC) remains a therapeutic

57 andscape of mitoribosomal proteins (MRPs) in nonsmall cell lung cancer (NSCLC) remains largely unchar

58 in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head a

59 Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few acti

60 ed that in different cancer types, including nonsmall cell lung cancer (NSCLC), the microRNA-183/96/1

61 practice in treating patients with advanced nonsmall cell lung cancer (NSCLC).

62 ith or without known effective therapies for nonsmall cell lung cancer (NSCLC).

63 hoblastic and myeloid leukemia (ALL/AML) and nonsmall cell lung cancer (NSCLC).

64 apy for patients with many cancers including nonsmall cell lung cancer (NSCLC).

65 ation with chemotherapy for the treatment of nonsmall cell lung cancer (NSCLC).

66 ficant improvement in the disease outcome of nonsmall cell lung cancer (NSCLC).

67 nistic aspect of this combination therapy in nonsmall cell lung cancer (NSCLC): that the DNMTi compon

68 antial proportion of the tumor mass in human nonsmall cell lung cancers (NSCLC), but the precise comp

69 smoking pack-years in a large collection of nonsmall-cell lung cancer (NSCLC) tumors.

70 w describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited

71 ) and induces dramatic clinical responses in nonsmall cell lung cancers (NSCLCs) with activating muta

72 utations in the BRAF kinase occur in 6-8% of nonsmall cell lung cancers (NSCLCs), accounting for more

73 ients, silent changes were identified in one nonsmall cell lung cancer, one prostate cancer, and one

74 duction of Ab, CD8(+), and CD4(+) T cells in nonsmall cell lung cancer patients vaccinated with MAGE-

75 e EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.

76 Using a nonsmall-cell lung cancer-related microRNA (hsa-miR-193a

77 nt population for colon cancer (all stages), nonsmall cell lung cancer (stage II), breast cancer (sta

78 It indicates that in advanced nonsmall-cell lung cancer survival, symptom control and

79 In nonsmall cell lung cancer, the presence of spontaneous U

80 tin remodeling complex, including SMARCA4 in nonsmall cell lung cancer with a frequency of up to 33%

81 In the nonsmall cell lung cancer xenograft model studied, a lin